UOC
AGIO icon

UBS O'Connor’s Agios Pharmaceuticals AGIO Stock Holding History

UBS O'Connor’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56,810
Closed -$1.89M – 279
2025
Q2 		$1.89M Sell
56,810
-1,912
-3% -$58K 0.05% 167
2025
Q1 		$1.72M Buy
58,722
+15,392
+36% +$511K 0.04% 138
2024
Q4 		$1.42M Buy
43,330
+22,243
+105% +$1.04M 0.04% 199
2024
Q3 		$937K Sell
21,087
-8,926
-30% -$405K 0.02% 286
2024
Q2 		$1.29M Sell
30,013
-49,893
-62% -$1.8M 0.04% 261
2024
Q1 		$2.34M Sell
79,906
-46,913
-37% -$1.26M 0.07% 152
2023
Q4 		$2.82M Buy
126,819
+21,598
+21% +$484K 0.09% 126
2023
Q3 		$2.6M Buy
105,221
+39,000
+59% +$1.03M 0.05% 193
2023
Q2 		$1.88M Buy
66,221
+13,721
+26% +$341K 0.04% 308
2023
Q1 		$1.21M Buy
52,500
+2,500
+5% +$66.4K 0.03% 387
2022
Q4 		$1.4M Buy
+50,000
New +$1.41M 0.03% 522
2016
Q2 		– Sell
-15,708
Closed -$638K – 401
2016
Q1 		$638K Buy
+15,708
New +$672K 0.01% 381
2013
Q4 		– Sell
-20,000
Closed -$559K – 404
2013
Q3 		$559K Buy
+20,000
New +$552K 0.01% 322

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

UBS O'Connor's AGIO Position: Q3 2025 in Review

UBS O'Connor sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 56,810 shares — an estimated $1.89M sold.

UBS O'Connor first reported a position in AGIO in Q3 2013 and held it in 13 quarters. The position peaked at $2.82M in Q4 2023. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • UBS O'Connor reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 56,810 Agios Pharmaceuticals shares in Q3 2025, an estimated $1.89M.
  • UBS O'Connor first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 13 quarters.
  • UBS O'Connor's Agios Pharmaceuticals position peaked at $2.82M in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.